By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MediGene AG 

Lochhamer Str. 11

Martinsried    82152   Germany
Phone: 49-89-85 65 29-00 Fax: 49-89-85 65 29-20



Company News
MediGene AG (MDGEF.PK) Receives Positive Decision On Marketing Authorisation For Veregen In 8 Additional European Countries 2/20/2015 11:01:02 AM
MediGene AG (MDGEF.PK) Receives Clinical Trial Approval For Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 12/22/2014 9:27:04 AM
MediGene AG (MDGEF.PK) To Participate In Three International Conferences In January 12/17/2014 9:49:13 AM
Clinical Data Of MediGene AG (MDGEF.PK)'s Dendritic Cell Vaccines To Be Presented At American Society of Hematology Conference 11/20/2014 11:10:21 AM
Initial Clinical Data On MediGene AG (MDGEF.PK)'s DC Vaccines To Be Presented At The SITC Conference 11/7/2014 11:27:30 AM
MediGene AG (MDGEF.PK)'s Subsidiary "Trianta Immunotherapies" Renamed "Medigene Immunotherapies" 11/7/2014 9:03:21 AM
MediGene AG (MDGEF.PK) To Participate In Five Investment And Scientific Conferences In November 11/3/2014 12:41:31 PM
MediGene AG (MDGEF.PK)'s Licensee Enters Promotion Agreement To Expand Veregen® Product Sales In The United States 10/30/2014 8:50:21 AM
MediGene AG (MDGEF.PK) Receives Patent For TCR-Modified T Cell Immunotherapy In Australia 10/8/2014 11:02:27 AM
MediGene AG (MDGEF.PK): Veregen® Marketing Authorization Process Initiated For Eight Additional European Countries 9/30/2014 9:06:32 AM